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ANALISIS ANTIGEN EKSKRETORI-SEKRETORI DARIPADA Entamoeba 
histolytica UNTUK PENGESANAN ABSES HATI AMEBA 
 
 ABSTRAK 
 
Amebiasis ialah penyakit protozoa usus yang disebabkan oleh Entamoeba 
histolytica. Ia melibatkan 50 juta orang di seluruh dunia dan menyebabkan 100,000 
kes kematian setiap tahun. Abses hati ameba (ALA) merupakan manifestasi klinikal 
yang paling lazim bagi amebiasis luar usus. Ia boleh menyebabkan kematian jika 
diagnosis dan rawatan terlewat. Sehingga sekarang, diagnosis untuk ALA masih 
bersandar kepada hasil keputusan sejarah klinikal, pengimejan radiologi, dan ujian 
diagnosis makmal. Ujian serologi tetap dijadikan pilihan kerana ia tidak invasif dan 
senang dijalankan. Namum, ujian serologi yang lazim digunakan, iaitu ‘indirect 
haemagglutination assay’ (IHA) dan ‘TechLab E. histolytica II ELISA’ 
menunjukkan sensitiviti yang rendah di kawasan endemik, disebabkan oleh latar 
belakang antibodi anti-ameba yang tinggi dalam populasi itu dan penerimaan 
rawatan terdahulu oleh pesakit. Oleh sebab itu, kajian ini bertujuan untuk 
menganalisis protein antigenik dalam antigen ekskretori-sekretori (ESA) E. 
histolytica, dan mengenalpasti satu penanda biologi yang berpontensi untuk 
menambah baik ujian serologi bagi ALA. 
 
Satu larutan media tanpa protein yang mengandungi 0.1 % L-cysteine dan 
0.02 % asid askorbik serta dapat memelihara ≥ 95 % trofozoit hidup bagi sekurang-
kurangnya 8 jam, iaitu DMEM-C&A atau RPMI-C&A telah dioptimum dan diguna 
untuk penyediaan ESA. Masa pengeraman trofozoit dalam larutan media itu telah 
dikurangkan kepada 6 jam bagi mengganti masa yang telah digunakan untuk 
XV 
 
mengumpul kultur trofozoit berskala besar. Ketumpatan maksimum trofozoit dalam 
medium ialah 0.8 x 10
6
 sel per mL. Kemudian, ESA dikumpul melalui proses 
pemekatan dan penukaran larutan penampan sebelum digunakan dalam analisis. 
Dalam analisis Western blot ESA yang diuji dengan serum manusia berpenyakit 
ALA (n = 38), dua antigenik protein menunjuk sensitiviti melebihi 80 %, iaitu 
protein 152 kDa dan 110 kDa. Spesifisiti kedua-dua protein ini ialah 100 % kerana 
tiada reaksi ditunjukkan apabila ianya diuji dengan serum manusia yang normal (n = 
30) dan jangkitan lain (n = 33), di mana IHAnya adalah negatif. Selain itu, analisis 
Western blot ESA yang diuji dengan serum daripada hamster berpenyakit ALA (n = 
9) menunjukkan protein antigenik 130 kDa, 110 kDa dan 100 kDa juga bereaksi 
dengan antibodi manusia. Analisis lanjutan dengan 2D-Western blot menunjukkan 
nilai pI bagi ketiga-tiga protein antigenic ini masing-masing ialah 5.33-5.91, 5.91-6.5 
dan 5.91-6.5. Keputusan daripada MALDI-TOF-TOF menunjukan protein 152 kDa 
ialah lektin E. histolytica yang telah dilaporkan sebelum ini dan 110 kDa ialah enzim 
piruvat fosfat dikinase E. histolytica. Protein 130 kDa tidak dapat dikenalpasti 
walaupun proses pemekatan protein telah dicuba, namun kandungannya dalam ESA 
sangat rendah. Kajian ini berjaya mengenalpasti satu protein daripada E. histolytica, 
iaitu 110 kDa protein yang berpotensi untuk digunakan dalam diagnosis ALA. 
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ANALYSIS OF EXCRETORY-SECRETORY ANTIGEN OF Entamoeba 
histolytica FOR DETECTION OF AMOEBIC LIVER ABSCESS 
 
 ABSTRACT 
 
Amoebiasis is an enteric protozoan disease caused by Entamoeba histolytica. It 
affects 50 million people worldwide and causes up to 100,000 fatal cases annually. 
Amoebic liver abscess (ALA) is the most common clinical manifestation of 
extraintestinal amoebiasis. It can lead to fatal outcome if early diagnosis and 
treatment are not obtained. To date, diagnosis of ALA is dependent on clinical 
history, radiological imaging, and laboratory diagnosis. Serodiagnosis is widely used 
because it is non-invasive and easy to perform. However, the commonly used 
immuno-haemagglutination assay (IHA) and TechLab E. histolytica II ELISA 
showed low sensitivities in endemic areas due to the high anti-amoebic antibody 
background in the population and prior treatment of patients. Thus, the aims of this 
study were to analyse the antigenic proteins of excretory-secretory antigen (ESA) 
collected from E. histolytica, and to identify potential biomarker(s) which could 
improve the serodiagnosis of ALA. 
 
A protein-free defined medium supplemented with 0.1 % L-cysteine and 0.02 
% ascorbic acid which could sustain the ≥ 95 % viability of the anaerobic trophozoite 
for at least 8 hours i.e. DMEM-C&A or RMPI-C&A was optimized and the latter 
used for ESA preparation. The incubation period of trophozoites in the medium was 
reduced to 6 hours, in order to compensate the time used for harvesting the mass 
cultured trophozoites. The maximum trophozoites density in the medium was 0.8 x 
10
6
 cells per mL. ESA was then collected, concentrated and buffer-exchanged prior 
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to use. Western blot analysis of ESA probed with human serum samples with ALA 
(n = 38) revealed two antigenic proteins with sensitivities above 80 %, i.e. 152 kDa 
and 110 kDa. Their specificities were 100 % as they were not recognised by normal 
human serum samples (n = 30) and other infections (n = 33) which were IHA 
negative. On the other hand, Western blot analysis of ESA probed with hamster 
serum samples with ALA (n = 9) revealed 130 kDa, 110 kDa and 100 kDa antigenic 
proteins which were also seen with human sera. Further 2D-Western blot analysis 
revealed that the pI values of these three antigenic proteins were 5.33-5.91, 5.91-6.5 
and 5.91-6.5, respectively. In the MALDI-TOF-TOF analysis, 152 kDa protein was 
identified as the E. histolytica lectin which has been previously reported, 110 kDa as 
E. histolytica pyruvate phosphate dikinase, while 130 kDa protein could not be 
identified due to its low amount in ESA despite efforts at concentrating it. Thus, this 
study has successfully identified that 110 kDa E. histolytica protein is potentially 
useful for diagnosis of ALA. 
 
 1 
 
 CHAPTER ONE 
 
 INTRODUCTION 
 
1.1 GENERAL 
Amoebiasis is an enteric protozoan disease caused by Entamoeba histolytica (WHO, 
1997). It is a cosmopolitan parasitic disease which affects 40-50 million individuals 
of the world population and causes up to 100,000 of fatal cases annually (Walsh, 
1986). It is the third common cause of death due to parasitic disease after malaria and 
schistosomiasis. It commonly occurs at places with poor sanitation and low socio-
economic conditions. The prevalence rate is higher in tropical and sub-tropical 
countries such as India, Mexico, and in South East Asia (Widmer and Nettleman, 
1991). 
 
The high risk groups for amoebiasis include travelers, male homosexuals and 
those with poor personal hygiene practice (Lazara Rojas Rivero et al., 2008). The 
transmission is worldwide due to the ease of world travel (Nari et al., 2008). Faecal 
oral route is responsible for the transmission through the ingestion of the infective 
stage cysts. On the other hand, human to human transmission through oral-genital or 
oral-anal contact also have been reported among homosexuals (Hung, 2007). Among 
10 % of the infected humans, only 10 % develops the clinical symptoms; while in the 
remainder the infection persists as asymptomatic carriers. Among the 10 % 
symptomatic patients, 90 % may present as intestinal amoebiasis and 10 % may 
develop into amoebic liver abscess (ALA). ALA is the most common clinical 
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manifestation of extraintestinal amoebiasis and potentially fatal if early diagnosis and 
treatment is not sought (Zlobl, 2001). 
 
According to a World Health Organization (WHO) report, the elementary 
means for eradicating of amoebiasis is basically based on the improvement of the 
quality of living conditions (e.g. clean water and food) and education (e.g. hand 
washing and personal hygiene) in the countries where amoebiasis is prevalent (Salles 
et al., 2003). This strategy was evidenced by the success of Cuba in eliminating 
malaria, schistosomiasis, leishmaniasis and Chagas by improving socioeconomic 
conditions, health, sanitation and water supply (Lazara Rojas Rivero et al., 2008). 
Similar to Malaysia, the statistics of parasitic disease had shown positive outcomes 
as the number of cases declined over the years after the implementation of 
socioeconomic development in the country. Nevertheless, the number of parasitic 
infections is relatively high in Malaysia as compared to the developed countries. For 
example, the prevalence of water-borne diseases among the aborigines, ‘Orang Asli’ 
is still high (Yusof and Ghani, 2009; Ministry-of-Health-Malaysia, 2006; Mak, 
2004). Therefore, continuous improvement of health program and monitoring of 
parasitic diseases are still needed. 
 
1.2 Entamoeba histolytica 
The trophozoite form of E. histolytica was described by Lösch in 1875 from a case of 
patient with chronic dysentery, whereby, Quincke and Roos later described its cyst 
form in 1893 (Marshall et al., 1997). The name Entamoeba histolytica for dysentery 
producing amoeba was named by Schaudinn in 1903. In 1925, Brumpt reported the 
presence of E. histolytica-like non-pathogenic strain E. dispar (Ackers, 2002; 
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Jackson, 1998; Brumpt, 1928). According to taxonomy classification, E. histolytica 
belongs to the kingdom protista, subkingdom protozoa, phylum sarcomastigophora, 
subphylum sarcodina, class lobosea, order amoebida, family endamoebidae, genus 
Entamoeba and species E. histolytica. It is a unicellular eukaryotic organism, 
containing nucleus and multiply through binary fission. It is also a heterotrophic and 
pleomorphic organism, in which it needs nutrient supplies from the environment and 
performs locomotion through pseudopodia movement. It is an endoparasite as it stays 
inside a host and preys for food like bacteria, red blood cells or food particles in host 
through formation of pseudopodia. Based on electrophoretic karyotyping via pulse 
gel electrophoresis, it was predicted that this parasite contains 14 chromosomes and 
with the genome size of c.a. 24 Mb (Loftus et al., 2005; Stanley, 2003; Baron, 1996).  
 
The life cycle of E. histolytica consisted of cyst and trophozoite, as shown in 
Figures 1.1 and 1.2. Upon entering into human digestive track, the cyst passes 
through the stomach and excysts at the distal end of ileum or colon where the 
quadrinucleate cyst is activated by the intestinal secretions and develops into four 
motile metacysts or metacystic trophozoites. Next, the motile trophozoites are 
formed and multiply via binary fission in the intestine. Under adverse condition, 
some of the trophozoites may undergo encystment. During encystment, the nucleus 
undergoes two division processes to produce a quadrinucleate cyst and may be 
excreted from the body in stool. The subsequent host may get infected when they 
ingest food or drink, contaminated with the cyst. Thus far, human and some none 
human primates are the only reported natural hosts (Rivera et al., 2010; Hankenson 
et al., 2003; Stanley, 2003).  
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Figure 1.1 Life cycle of E. histolytica (CDC, 2010) 
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Figure 1.2  Morphological descriptions of E. histolytica trophozoite and cyst 
(CDC, 2010) 
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The cyst is the infective dormant stage and resistant to environmental stresses 
(e.g. oxygen, gastric acid). It is round in shape, 10-20 µm in diameter, and enclosed 
by a retractile wall. A mature cyst contains four nuclei. Each nucleus consists of a 
central karyosome surrounded by peripheral chromatin. Rod-like chromatoid bodies 
made of the assemblies of glycogen and ribosome may also be present, but they are 
more common in immature cysts. On the other hand, the trophozoite of E. histolytica 
is actively multiplying and highly motile in human host. Its size is generally 10-60 
µm and pleomorphic in shape. It is an anaerobic organism and does not possess 
mitochondria. The main energy source of trophozoites is acquired from the anaerobic 
conversion of glucose and pyruvate to ethanol. Red blood cells and/or bacteria are 
sometimes found in the endoplasm. Under permanent trichrome stain, the nucleus 
contains a distinctive central karyosome and surrounded by a delicate distinct 
membrane with beaded chromatin (Lohia, 2003). 
 
1.2.1 Transmission 
Generally, E. histolytica is transmitted via faecal oral route through the ingestion of 
food and/or water contaminated with cysts, which could come from food handlers, 
house flies, cockroaches, and the use of human excreta as fertilizers for growing 
vegetables and fruits (Hankenson et al., 2003). Amoebiasis could also be transmitted 
among homosexuals via oral-genital or oral-anal contact. The life span of 
trophozoites in stool is rather short. However, the cysts are more robust, resistant to 
environmental pressure, and able to survive in stool for up to about 12 days. High 
incidence of amoebiasis occurs among those between 26 – 30 years old as compared 
to children below 5 years old. The incidents of ALA are higher in males than females 
with a ratio of 10:1 or higher (Lee et al., 2009; Akgun et al., 1999).  
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1.2.2 Clinical Manifestations and Pathogenesis  
The pathogenesis of amoebiasis is highly dependent on the virulence of trophozoites 
and host-parasite interaction. The clinical presentations of the individual infected by 
E. histolytica are wide as shown in Table 1.1. The trophozoites may just reside in the 
infected individual as commensally organism without tissue invasion. If mucosal 
invasion occurs, the clinical manifestation may vary from local mucosal erosion to 
mucosal ulceration depending on depth of the invasion. Mucosal erosion may lead to 
diarrhoea and the severity increased with the area of the affected colon. If the lesions 
are toward the distal part of the colon, it is more likely the individual will have the 
symptoms of intestinal amoebiasis, instead of asymptomatic local caecal lesion. 
When the rectal bleeding occurs, the blood in the faecal specimen may be occult, 
which is demonstrable only by chemical testing. The individual may also experience 
abdominal tenderness or cramping pain. 
 
The invasion of trophozoites often started at the intestinal compartment and 
progress to extraintestinal if the trophozoites break into the blood stream. In the 
benign phase of intestinal amoebiasis, the individual will experience mild to severe 
diarrhoea, which is also classified as non-dysenteric colitis. However, when the area 
and depth of lesion increase, diarrhoea will be replaced by dysenteric stools, which 
consist largely of mucous and blood without faeces. The affected individual may 
experience fever, dehydration, and electrolytes imbalance. Occasionally, but less 
frequently, local invasion of trophozoites will evoke a proliferative granulomatous 
response at the ulcerative site and turn into pseudo-tumor, known as amoeboma. 
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Extraintestinal amoebiasis is results from the haematogenous spread of 
trophozoites to liver, lung, brain or skin. ALA is the most common clinical 
manifestation which is due to the metastasis of trophozoites to liver through the 
portal vein. A focal amoebic abscess in the liver would be sufficient to represent the 
metastasis of trophozoites from intestine to liver. Intestinal amoebiasis symptoms 
need not be present simultaneously. The size of the abscess may grow bigger with 
the enlargement of the liver mass in a symptomatic patient. The individual may 
experience right upper quadrant pain, tenderness of the liver, fever, jaundice and 
nausea. Fatality may occur if early diagnosis and treatment are not sought.  
 
1.2.3 Host Parasite Interaction 
The actual mechanism of host defence against E. histolytica remains unclear. Both 
innate and acquired immunity are reported to be important for prevention of 
amoebiasis. The first defence of amoebiasis in human is the mucosal layer of 
intestine, which serves to prevent contact between trophozoites and intestinal 
epithelial cells. Passive immunity is also contributed by the natural flora present in 
human intestine.  They compete with the trophozoites to adhere to host colonic cells. 
Often, cell mediated immunity is polarized toward Th1 immune response, in which 
they limit the extent of invasive amoebiasis and protect the host from recurrent 
infection following recovery from the disease (Supali et al., 2010; Solaymani-
Mohammadi and Petri, 2008). 
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Table 1.1 Classification of amoebiasis 
 
 WHO Clinical Classification of 
Amoebiasis Infection 
Pathophysiologic Mechanism 
Asymptomatic infection 
 
Symptomatic infection 
  
 Intestinal amoebiasis 
 A. Amoebic dysentery 
 B. Nondysenteric gastroenteritis 
 C. Amoeboma 
 D. Complicated intestinal 
 amoebiasis 
 E. Post-amoebic colitis 
  
 Extraintestinal amoebiasis 
 A. Nonspecific hepatomegaly 
 
 B. Acute nonspecific infection 
 C. Amoebic abscess 
 D. Amoebic abscess   
 complicated 
 E. Amoebic cutis 
 F. Visceral amoebiasis 
Colonization without tissue invasion 
 
Invasive infection 
 
 
Fulminant ulcerative intestinal disease 
Ulcerative intestinal disease 
Proliferative intestinal disease 
Perforation, haemorrhage, fistula 
 
Mechanism unknown 
 
 
Intestinal infection with no demonstrable 
invasion 
Amoebas in liver but without abscess 
Focal structural lesion 
Direct extension to pleura, lung, 
peritoneum, or pericardium 
Direct extension to skin 
Metastatic infection of lung, spleen, or 
brain 
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On the other hand, the resistance of trophozoites and its virulence factors are 
the key factors for disease development and progression. The virulence factors of E. 
histolytica included Gal/GalNAc lectin, proteases, and amoebapores. Gal/GalNAc 
lectin is a surface membrane protein that assists the adherence of trophozoites to the 
host cell via high affinity binding to the O-linked protein, galactose (Gal) and N-
acetyl-D-galactosamine (NAcGal) present in the mucosal layer of intestine. This 
lectin has been shown to contribute to lysis of host cells through contact-dependent 
killing via apoptosis. Following adherence of trophozoites onto the mucosal surface, 
it secretes proteases that contribute to the erosion of intestinal mucus by disruption of 
mucin 2 (MUC2) polymerization. These proteases are able to rapidly degrade the 
mucosal IgA and serum IgG (Garcia-Nieto et al., 2008; Garcia-Zepeda et al., 2007; 
Tarleton and Petri, 2004; Tran et al., 1998). The trophozoites also secrete an 
amoebapore, a pore-forming protein which lysed host cells. Besides, the lysed cells 
like neutrophils and granulocytes also release toxic products that further increase 
host cell tissue destruction (Leippe and Herbst, 2004). A recent study showed that the 
trophozoites expressed CD59-like protein on its surface to protect itself against the 
cytolytic action of the membrane attack complex, by inhibiting the polymerization of 
the C9 protein, which is responsible for the modification of membrane phospholipid 
layer (Ventura-Juarez et al., 2009; Zambrano-Villa et al., 2002).  
 
1.2.4 Serological Immune Response of Amoebiasis in Human 
Immune responses of human with amoebiasis are complex due to the wide range of 
its clinical presentation. Upon the invasion of E. histolytica, the immune response of 
human is elicited within seven days (Kaur et al., 2004). As a sign of mucosal 
invasion, IgA is secreted in the mucosal layer of intestine (Haque et al., 2003). It has 
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been shown that high level of mucosal-IgA, saliva-IgA and serum-IgG may persist 
for at least one year after treatment. The levels of these antibodies are higher in 
patients with ALA as compared to amoebic dysentery cases. These persistent 
antibodies contribute to the background anti-amoebic antibodies among population in 
endemic areas. Besides, recurrent infection often occur (Haque and Petri, 2006; 
Valenzuela et al., 2001; Haque et al., 1997). Higher level of anti-lectin antibodies 
was reported in patients with amoebic dysentery and ALA, as compared to 
asymptomatic cysts passer. In ALA cases, high level of IgG1 (60 % of total anti-
lectin IgG) was found to be present, which suggested Th2 immune response; while 
high level of IgG1 (40 % of total anti-lectin IgG) and IgG4 (30 % of total anti-lectin 
IgG) were found to be present in both patients with intestinal amoebiasis and 
asymptomatic cysts passer (Kaur et al., 2004). The level of IgM was higher in cases 
of intestinal amoebiasis, as compared to ALA and asymptomatic cyst passer. High 
level of anti-amoebic antibodies was reported in endemic areas, but recurrent 
infections still occur and unremitted in many patients. Therefore the protection roles 
of these antibodies against E. histolytica remain controversial (Tarleton and Petri, 
2004; Trissl, 1982).  
 
1.2.5 Other Amoebas 
Besides the parasitic amoeba that requires host, there are free living species as well, 
i.e. Naegleria spp., Acantamoeba spp., Balamuthia mandrillaris and Sappinia 
diploidea (Schuster and Visvesvara, 2004; Schuster, 2002). Several species of these 
non-pathogenic amoebas are reported to be found in human body, i.e. E. polecki, 
Iodamoeba butschlii, E. coli, E. moshkovskii, E. gingivalis, E. chattoni and 
Endolimax nana (Zlobl, 2001). Table 1.2 shows the description of the features and 
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characteristics of the amoebas found in human intestine. Figure 1.3 shows the 
morphology of the amoebas that could be found in humans stool samples. Since the 
discovery of the morphologically identical but genetically different E. dispar, the 
result from microscopy is no longer specific for detection of E. histolytica. However 
erythrophagocyted trophozoites are suggested to highly correlate with the presence 
of E. histolytica and invasive disease. E. dispar had been classified by WHO as the 
non-pathogenic strain (WHO, 1997). 
 
1.3 CLINICAL DIAGNOSIS OF AMOEBIASIS 
The clinical diagnosis of individual infected with E. histolytica could be categorized 
into three groups based on their clinical manifestations, i.e. asymptomatic carrier, 
intestinal amoebiasis and extraintestinal amoebiasis.  
 
1.3.1 Asymptomatic Carrier 
Asymptomatic carriers are those with no signs and symptoms of either intestinal or 
extraintestinal amoebiasis, but with the presence of E. histolytica trophozoites or 
cysts in the intestine or stool. Majority of the affected people falls into this category. 
They are detected by microscopy examination of trophozoites and/or cysts in the 
stool. Since microscopy could not distinguish among species of pathogenic/non-
pathogenic Entamoeba, the application of DNA-based or stool antigen detection test 
is highly recommended (Baron, 1996). 
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Table 1.2 Morphologic features and pathogenicity of intestinal amoeba (Tanyuksel and Petri, 2003) 
 
Characteristics E. histolytica, E. dispar and E. 
moshkovskii
a 
E. hartmanni E. coli E. polecki E. nana 
Trophozoites (size, 
nucleus, and 
movement) 
15-20 μm; 1 nucleus; actively motile 
cytoplasmic protrusions, quickly 
finger shaped pseudopodium 
8-10 μm; 1 nucleus; 
nonsuccessive 
20-25 μm; 1 nucleus; 
slow movement, short 
and blunt 
pseudopodium 
15-20 μm; 1 nucleus; 
motility resembles E. coli 
7-9 μm; 1 nucleus, 
blunt and hyaline 
pseudopodium, slow 
movements 
Cysts (size, 
nucleus) 
12-15 μm; mature cyst has 4 nuclei, 
immature cyst has 1 or 2 nuclei 
6-8 μm; mature cyst 
has 4 nuclei; immature 
cyst has 1 or 2 nuclei; 2 
nucleated cysts very 
common 
15-25 μm; mature cyst 
has 8 nuclei, rarely 16 
or more nuclei 
10-15 μm; 1 nucleus, very 
rarely binucleated or 
quadrinucleated 
6-8 μm; 4 nuclei 
Appearance of 
trophozoites 
Stained trophozoites with fine, 
uniform granules of peripheral 
chromatin, and small central 
karyosome in nucleus; ingested RBC 
(E. dispar and E. moshkovskii are 
similar to E. histolytica trophozoites, 
sometimes ingested RBCs) 
Nuclear structure 
similar to E. 
histolytica; cytoplasm 
finely granular; 
ingested bacteria 
Nuclear with irregular 
cluster of peripheral 
chromatin; large, 
irregular, eccentric 
karyosome 
Nucleus with minute 
central karyosome, with 
fine granules of peripheral 
chromatin, finely granular 
cytoplasm; ingested 
bacteria 
Nucleus with large 
karyosome; no 
peripheral chromatin 
Appearance of 
cysts 
Typical nuclear structure is uniform 
size in having both karyosome and 
peripheral chromatin, chromatoidal 
bars with squared or rounded ends 
Typical nuclear 
structure, chromatoidal 
bars with rounded or 
squared ends 
Typical nuclear 
structure, sliver-
shaped or irregular 
chromatoidals 
Mononucleated; large 
central karyosome; 
chromatoid bars with 
pointed or angular ends, 
inclusion masses 
Chromatin, 4 nuclei 
with large 
karyosomes and no 
peripheral chromatin 
Pathogenicity Only E. histolytica is pathogenic (E. 
dispar and E. moshkovskii are 
nonpathogenic) 
Nonpathogenic Nonpathogenic Nonpathogenic Nonpathogenic 
a
E. moshkovskii is present in free-living protozoa. 
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Figure 1.3 Amoebas found in stool specimens of humans (Baron, 1996) 
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1.3.2 Intestinal Amoebiasis 
Intestinal amoebiasis may present as amoebic colitis or amoebic dysentery. In cases 
suspected of intestinal amoebiasis, stool samples for three consecutive days are 
collected and sent for microscopy examination. Negative result from single samples 
does not rule out the possibility of amoebic infection. Polyvinyl alcohol (PVA) 
fixative or Schaudinn’s fixative should be used during the stool specimen collection 
to preserve the fragile and rapid deteriorating trophozoites. However, direct wet 
mount on fresh stool samples are commonly performed in many laboratories to save 
cost and time, but the sensitivity is low. Therefore concentration techniques such as 
zinc sulfate flotation technique and formalin ether sedimentation technique should be 
performed on ‘negative’ samples to decrease the possibility of false negative result. 
In many cases, live trophozoites could not be detected via concentration technique, 
as many will deteriorate during the process. Antigen detection tests like Techlab E. 
histolytica II and ProSpecT Entamoeba histolytica are more sensitive, but they are 
not routinely used in most of the developing counties due to the high cost. Figure 1.4 
(A) shows the flowchart for clinical diagnosis of intestinal amoebiasis.  
 
The clinical presentation of intestinal amoebiasis may be similar to enteric 
bacteria disease e.g. salmonellosis, shigellosis, enteropathogenic or 
enterohaemorrhagic Escherichia coli, as well as noninfectious inflammatory bowel 
disease and ischemic colitis. Besides, amoebic colitis can also be confused with the 
clinical presentation of Crohn’s disease. It is important to rule out Crohn’s disease 
prior to treatment with corticosteroid therapy as the treatment will worsen the 
condition of patient (Baron, 1996). 
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Figure 1.4 Classical flow chart for diagnosis of amoebiasis 
A. Intestinal amoebiasis; B. Extraintestinal amoebiasis 
  
B Clinical Manifestations 
Radiological Imaging 
(Ultrasound, CT-scan, Isotope-scan) 
Without Abscess 
Other Etiologies 
With Abscess 
Serology Test 
Positive 
Treat 
Negative 
Examination of Aspirated 
Pus/Abscess  
Positive 
Treat 
Negative 
Other Etiologies 
A 
Clinical Manifestations 
Specimen Collection and Preservation 
(3 Consecutive Days) 
Microscopy 
Examination Positive 
Microscopy 
Examination Negative 
Stool Concentration Technique 
Positive Negative 
Treat 
Other Etiologies Treat 
Stool Antigen Detection 
Positive 
Treat 
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1.3.3 Extraintestinal Amoebiasis 
The examination for extraintestinal amoebiasis is often started when patient 
experiences the symptoms of fever, nausea, hepatomegaly and tenderness in the right 
upper quadrant. Radiological imaging is performed to investigate the presence and 
size of the abscess. Depending on the physical condition of the patient and size of the 
abscess; the physician may aspirate the abscess for microscopy examination to check 
for the presence of live trophozoites, and also to rule out the possibility of liver 
necrosis. Culture of the abscess is also performed to rule out the possibility of 
pyogenic liver abscess that are caused by bacteria such as E. coli, Klebsiella spp., 
Staphylococcus spp. and Streptococcus spp. Live trophozoite is rarely found in the 
microscopy examination of aspirated pus as it is easily disintegrated and tendency of 
the trophozoites to line the peripheral margin of abscess, instead of the center part 
(Salles et al., 2003). The trials to harvest the trophozoites at the peripheral margin of 
abscess are ethically inappropriate, as this may harm the unnecessary normal liver 
tissue. Furthermore, for extraintestinal amoebiasis cases, the symptoms of intestinal 
amoebiasis may not be present, and trophozoites and cysts are rarely found in the 
stool samples. Therefore, many physicians often treat the patient based on the 
combination of clinical manifestations, serological test and radiological imaging. 
Figure 1.4 (B) shows the simple flowchart for diagnosis of extraintestinal amoebiasis 
(Baron, 1996). 
 
1.4 TREATMENT FOR AMOEBIASIS 
Upon confirmation of diagnosis, physicians will prescribe drugs for treatment of 
patient. The drugs for treatment of intestinal and extraintestinal amoebiasis are 
shown in Tables 1.3 and 1.4. Each of the drugs has its side effects (Abdi et al., 1995). 
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Physical condition of patient e.g. pregnancy will be taken into consideration prior to 
prescribing the drug. In asymptomatic carrier, once the E. histolytica species are 
confirmed, the patient should be treated to prevent spreading of the infective stage 
cysts. The drugs of choice included iodoquinol, paromomycin, and diloxanide 
furoate. The treatment for intestinal amoebiasis is similar to asymptomatic carrier. 
However, as the disease progress from mild intestinal amoebiasis to severe intestinal 
amoebiasis such as amoeboma or acute dysentery, the drug of choice will be 
tinidazole, metronidazole or paromomycin, in which the side effect will be greater. 
 
The most common drug for treatment of extraintestinal amoebiasis is 
metronidazole. It is a highly lethal drug for anaerobic organism e.g. protozoa and 
bacteria. Besides, it also showed optimum pharmacokinetic features, in which it is 
easily absorbed in the intestine, has high bioavailability, wide systemic distribution 
including internal part of the abscess, and with a half-life of 14 hours. The dosage of 
the drugs that is effective for liver abscess is four times the minimum inhibitory 
concentration for the trophozoites. The drug can be administrated orally or by 
intravenous injection. The prescription for oral route is 750 mg of metronidazole, 
three times daily for 10 days for adult and 50 mg/kg/day for children. Whereby, 500 
mg of metronidazole is introduced by intravenous infusion every 8 hours for 5 or 10 
days. The common side effects of metronidazole include nausea, vomiting, headache 
and abdominal discomfort. Metronidazole should not be given to pregnant women 
during the first trimester of pregnancy and breastfeeding, as the drug is able to cross 
the placenta and able to enter breast milk. However, if amoebiasis is diagnosed in 
pregnant women, metronidazole is still the drug of choice but close follow up is 
needed (Salles et al., 2003; Upcroft and Upcroft, 2001; Zlobl, 2001).   
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Table 1.3 Drugs treatment for amoebiasis (The-Medical-Letter, 2010) 
 
Clinical 
Classification 
Drug of Choice Dosage 
Adult Pediatric 
Asymptomatic 
Carrier 
Iodoquinol 
 
 
 
OR 
Paromomycin 
 
OR 
Diloxanide furoate 
650 mg PO tid x 20d 
 
 
 
25-35 mg/kg/d PO in 3 
doses x 7d 
 
500 mg PO tid x 10d  
30-40 mg/kg/d 
(max 2g) PO in 3 
doses x 20d 
 
25-35 mg/kg/d PO 
in 3 doses x 7d 
 
20 mg/kg/d PO in 
3 doses x 10d 
 
Mild to Moderate 
Intestinal Amoebiasis 
Metronidazole 
 
 
OR 
Tinidazole 
 
 
(Either followed 
by Iodoquinol) 
 
 
OR 
Paromomycin 
 
500-750 mg PO tid x 7-
10d 
 
2 g once PO daily x 3d 
 
 
 
650 mg PO tid x 20d 
 
 
 
25-35 mg/kg/d PO in 3 
doses x 7d 
35-50 mg/kg/d PO 
in 3 doses x 7-10d 
 
≥ 3yrs: 50 mg/kg/d 
(max 2g) once PO 
x 3d 
 
30-40 mg/kg/d 
(max 2g) PO in 3 
doses x 20d 
 
25-35 mg/kg/d PO 
in 3 doses x 7d 
Severe Intestinal and 
Extraintestinal 
Amoebiasis 
Metronidazole 
 
OR 
Tinidazole 
 
 
OR 
(Either followed 
by Iodoquinol) 
 
OR 
Paromomycin 
750 mg PO tid x 7-10d 
 
 
2 g once PO daily x 5d 
 
 
 
650 mg PO tid x 20d 
 
 
 
25-35 mg/kg/d PO in 3 
doses x 7d 
35-50 mg/kg/d PO 
in 3 doses x 7-10d 
 
≥ 3yrs: 50 mg/kg/d 
(max 2g) PO in 1 
dose x 3d 
 
30-40 mg/kg/d 
(max 2g) PO in 3 
doses x 20d 
 
25-35 mg/kg/d PO 
in 3 doses x 7d 
 
Note: Tid (thrice a day), d (day), PO (by mouth) 
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Table 1.4 Mechanism and adverse effect of treatment drug for amoebiasis 
(Stanley, 2003) 
 
Drug Mechanism Adverse Effect Comments 
Metronidazole  
Or Tinidazole 
Activated in anaerobic 
organisms by 
reduction of the 5-nitro 
group. Activated 
compound damages 
DNA  
Metallic taste, nausea, 
vomiting, diarrhea. 
(Rarely result in 
sensory neuropathies, 
central nervous system 
toxicity with ataxia, 
vertigo, seizures and 
encephalopathy.) 
 
Drug of choice for 
amoebic colitis and 
ALA. 
Paromomycin Aminoglycoside 
(inhibit protein 
synthesis) 
Nausea, vomiting, 
cramps, diarrhea 
Drug of choice for 
intestinal amoebiasis. 
It should be 
administrated to all 
individuals following 
completion of 
metronidazole therapy.  
 
Iodoquinol  
 
unknown Headache, nausea, 
vomiting. Optic nerve 
damage and peripheral 
neuropathy reported in 
patient exceeding 
recommended dosage 
 
Alternative to 
paromomycin 
Diloxanide 
Furoate 
unknown Flatulence Alternative to 
paromomycin 
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1.5 LABORATORY DIAGNOSIS OF AMOEBIASIS 
Conventional diagnosis for amoebiasis is based on microscopy and isoenzyme 
analysis. With the advancement of technology, there were remarkable developments 
in molecular biology-based diagnostic tests for detection of E. histolytica including 
enzyme-linked immunosorbent assay (ELISA), indirect haemagglutination assay 
(IHA) and latex agglutination. With the advent of rapid diagnostic platforms, 
research on diagnostic kits that enhance point-of-care has also been initiated (Fotedar 
et al., 2007; Petri and Singh, 1999). 
 
1.5.1 Microscopy 
Before molecular techniques were introduced, the diagnosis of amoebiasis is mainly 
based on clinical syndrome and microscopic examination of stool samples, which 
posed many problems. First, amoebiasis is often clinically under-diagnosed in 
developing areas, unless there is history of the patients returning from tropical area. 
Second, there is poor correlation between patients infected with amoeba and the 
development of symptomatic amoebiasis, as 90 % of infected individuals present as 
asymptomatic carriers (Barrett-Connor, 1971). 
 
Besides, before the morphological similarity with the non-pathogenic strain, 
E. dispar was discovered, over-diagnosis and over-treatment were common. The 
third problem is the poor sensitivity of laboratory methods and low laboratory 
proficiency. Furthermore, stool examination require fresh samples as well as trained 
personnel to interpret the result (Mukhopadhyay et al., 2000; Barrett-Connor, 1971). 
However, microscopic examination of stool samples for the protozoan morphology is 
still commonly practiced in many parasitology laboratories, especially in 
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underdeveloped countries. It is mainly applied for diagnosis of intestinal amoebiasis 
but not extraintestinal amoebiasis, unless intestinal symptoms are present as well. It 
is difficult or even impossible to microscopically differentiate among all the human 
intestinal protozoa with similar morphological features, as shown in Figure 1.3 and 
Table 1.2. Thus, the sensitivity and specificity of microscopy examination for 
detection of E. histolytica in stool are low, due to the possibilities of misdiagnosis 
with other similar species i.e. E. dispar and E. moshkovskii (Liang et al., 2009; 
Haque and Petri, 2006; Tanyuksel and Petri, 2003; WHO, 1997; Haque et al., 1995). 
 
The probable differential diagnosis based on microscopic identification of E. 
histolytica is the presence of trophozoites with red blood cells in dysenteric stool. 
However, the presence of trophozoites with ingested red blood cells is not frequent in 
all the intestinal cases. The possibilities of observing trophozoites is higher in loose 
stool which contained mucous, pus and trace amount of occult blood, whereas cysts 
could be observed in both formed and loose stools. The fresh stool samples must be 
processed fast as the trophozoites are rapidly disintegrated. If examination could not 
be performed immediately, the stools should be preserved in PVA or Schaudinn’s 
fixative (Garcia and Shimizu, 1998). 
 
The microscopy examination of stool samples can be performed directly or 
after staining. For direct stool examination, wet mount is commonly performed. The 
trophozoites and cysts can be easily identified, but the nucleus or central karyosome 
is difficult to see. With Lugol’s iodine stain the internal features of the trophozoites 
and cyst are easily visible. Other stains e.g. methylene blue, Giemsa, Wright’s and 
iodine-trichrome may be used for the staining as well, but Wheatley’s trichrome 
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staining and modified iron haematoxylin permanent stain have been suggested for 
routine used (Fotedar et al., 2007). In Wheatley’s trichrome staining, trophozoites in 
stool samples are stained blue purple, while the background is stained light green. In 
addition, this stain also displays good chromatin lining and central karyosome of the 
nucleus. A recent study introduced an easy to perform Eosin Y staining method for 
trophozoites (E. histolytica/E. dispar/E. moshkovskii) in stool samples. The 
characteristic features of the amoeba are easily identified. The trophozoites are 
stained light red in stool samples, while the central karyosome and chromatin 
materials are stained distinctly dark in colour. This stain is suggested to be suitable 
for routine diagnosis as it is easy to perform and rapid. However, it is not for long 
term record keeping, as the stain fades away after one month (Tan et al., 2010). 
 
1.5.2 Biochemical Method: Culture and Isoenzyme Analysis 
Culture of E. histolytica in artificial media e.g. Locke-egg medium, TYSGM-9, and 
TYI-S-33, followed by isoenzyme analysis has long been performed in many 
laboratories as the gold standard because it is able to differentiate between the 
pathogenic and non-pathogenic strains of Entamoeba spp. Four of the glycolytic 
enzymes namely hexokinase, phosphoglucomutase, glucose-6-phosphate isomerase 
(GPI), and malic enzyme have been applied in the isoenzyme analysis (Razmjou et 
al., 2006). A total of 24 different zymodemes (isoenzyme analysis patterns) have 
been established, in which 21 zymodemes are from human isolates (9 patterns for E. 
histolytica and 12 patterns for E. dispar) and 3 are from experimentally cultured 
amoeba strains. Zymodeme is reliable in differentiation of E. histolytica and E. 
dispar due to the genetically different hexokinase enzymes between the species. The 
drawbacks of this method in laboratory diagnosis include being laboratory intensive 
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and time consuming. This method may need four to ten days to grow the trophozoites 
to a significant amount prior to starch-gel electrophoresis, and furthermore the 
culture may not always be successful (Haque and Petri, 2006; Ackers, 2002). 
Moreover, bacteria or other intestinal protist e.g. Blastocystis hominis may overgrow 
during the culture of trophozoites, and thereby affect the result of the zymodeme. 
The usage of this technique is now mainly for research purpose or epidemiological 
study (Fotedar et al., 2007; Gatti et al., 2002).  
 
1.5.3 Antibody Detection 
Serological method is commonly used in many laboratories for diagnosis of 
amoebiasis as the serum samples could be easily obtained and it is relatively less 
invasive. In endemic area, the detection of antibodies may be difficult due to the 
persistent high background antibody titer in the population. It is also usually unable 
to distinguish recent infection from past infection (Pillai et al., 1999). Thus, 
serological result could only be as a supporting evidence for physician’s diagnosis. In 
contrast, antibody detection method is effective for invasive amoebiasis cases in 
developed countries, as most of the individuals have no history of past infection. 
 
In ALA, detection of anti-amoebic antibodies in serum samples was claimed 
to be ~100 % in sensitivity. Therefore, serological method is still a promising choice 
for diagnosis, together with other evidences from clinical manifestations and 
radiological imaging. The available antibody detection tests include ELISA, IHA, 
counterimmunoelectrophoresis (CIE), amoebic gel diffusion, complement fixation 
(CF), indirect fluorescent assay and latex agglutination. Nevertheless, the commonly 
used formats for diagnosis of amoebiasis are ELISA and IHA.  
